

Eli Lilly & Company (LLY)

\$141.52 (As of 06/15/20)

Price Target (6-12 Months): **\$162.00**

Long Term: 6-12 Months

Zacks Recommendation:

Outperform

(Since: 03/31/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5)

1-Strong Buy

Zacks Style Scores:

VGM:C

Value: C


Growth: D

Momentum: C

Summary

Lilly's enjoys strong presence across a wide range of therapeutic areas and boasts a strong diabetes portfolio. Lilly expects the economic consequences of the coronavirus pandemic to hurt its profits in 2020. Nonetheless, Lilly still expects revenue growth to be driven by higher demand for its growth drugs like Trulicity, Taltz, and others. Lilly is making significant pipeline progress with several positive late-stage data readouts scheduled for 2020. Lilly is also regularly adding promising new pipeline assets through business development deals. However, generic competition for several drugs, rising pricing pressure in the United States, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds expected in 2020. The stock has outperformed the industry this year so far.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$164.90 - \$101.36
20 Day Average Volume (sh)	4,025,953
Market Cap	\$135.4 B
YTD Price Change	7.7%
Beta	0.24
Dividend / Div Yld	\$2.96 / 2.1%
Industry	Large Cap Pharmaceuticals
Zacks Industry Rank	Top 6% (15 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	12.9%
Last Sales Surprise	6.3%
EPS F1 Est- 4 week change	0.0%
Expected Report Date	07/30/2020
Earnings ESP	0.0%
P/E TTM	21.9
P/E F1	20.8
PEG F1	2.0
P/S TTM	5.9

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021					25,424 E
2020	5,860 A	5,808 E	5,816 E	6,577 E	23,934 E
2019	5,092 A	5,637 A	5,477 A	6,114 A	22,320 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021					\$8.02 E
2020	\$1.75 A	\$1.60 E	\$1.76 E	\$1.75 E	\$6.81 E
2019	\$1.33 A	\$1.50 A	\$1.48 A	\$1.73 A	\$6.04 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 06/15/2020. The reports text is as of 06/16/2020.

Overview

Indianapolis, IN based Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise.


Its pharmaceutical product categories are neuroscience (Zyprexa, Cymbalta, Emgality), diabetes (Humalog, Humulin, Trulicity and others), oncology (Alimta, Cyramza, Verzenio), immunology (Taltz and Olumiant) and others (Cialis).

Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The \$6.5 billion purchase of ImClone Systems in November 2008 brought with it blockbuster cancer compound, Erbitux. The January 2007 acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc. (a neuroscience drug discovery company focused on sleep disorders), CoLucid Pharmaceuticals (which added lasmiditan for acute migraine) and Loxo Oncology (added selpercatinib for RET-altered lung and thyroid cancers).

Lilly has collaboration agreements with several companies including Pfizer (tanezumab), Incyte (Olumiant), Boehringer Ingelheim (diabetes), among others.

Lilly divested its Elanco animal health unit as an independent publicly traded company - Elanco Animal Health Incorporated - via an initial public offering (IPO) of a minority stake in 2018. Elanco Animal Health started trading with the ticker symbol ELAN on NYSE from Sep 20. Lilly divested the remaining 80.2% stake in the new company through a "tax-efficient transaction" in March 2019.

Lilly's 2019 revenues increased 4% to \$22.3 billion. Among the key drugs, Trulicity accounted for 18% of Lilly's 2019 revenues, Humalog accounted for around 13%, Alimta accounted for 9% and Taltz accounted for 6% of the top line.



Reasons To Buy:

▲ **Shares Outperforming Industry:** Lilly's share price has risen 7.7% this year so far, outperforming the industry's decrease of 5.0%.

▲ **Key Products Target a Wide Range of Therapeutic Areas:** Lilly boasts of a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on central nervous system disorders, metabolic diseases, autoimmune diseases, cardiovascular diseases and cancer, which are all high growth areas and represent significant commercial potential.

▲ **Successful Diabetes Business:** Lilly has a strong portfolio of medicines to treat diabetes that includes drugs like Tradjenta, Jardiance, Trulicity, Synjardy, Synjardy XR, Glyxambi (a fixed dose combination of Jardiance/metformin), Basalgar and Humalog U-200 KwikPen. Trulicity, its highest revenue generating product, recorded sales of \$4.1 billion in 2019. With the inclusion of the cardiovascular indication in Jardiance's label in 2017, there has been a surge in the drug's sales. Lilly is also developing an automated insulin delivery system (phase II) to automate insulin dosing in type I diabetes in order to make diabetes management easier. It also launched Insulin Lispro, a lower priced version of Humalog in the United States in May 2019 and lower-priced versions of Humalog Mix75/25 and KwikPen and Humalog Junior KwikPen in April.

▲ **Working on Building Its Pipeline:** Lilly has been working on building its pipeline and has a wide range of compounds in different stages of development. Lilly believes it has the potential to launch 20 new products in a 10-year time frame from 2014 through 2023. The company is also looking to launch an average of two new indications or line extensions for approved products every year during this time period.

Lilly's key areas of focus are diabetes, oncology, immunology and neurodegeneration. Notable pipeline agents include tanezumab (osteoarthritis pain – under review in United States and Europe, cancer pain - phase III), mirikizumab (psoriasis – phase III, ulcerative colitis – phase III and Crohn's disease – phase III) and lebrikizumab (atopic dermatitis – phase III). A novel diabetes candidate in Lilly's pipeline is tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), which showed impressive blood sugar reductions and weight loss in type II diabetes patients in October. Phase III studies began in late 2018. The company also initiated a cardiovascular outcome study for tirzepatide in June 2020. Tirzepatide is also in phase III studies for obesity and phase II in NASH.

New drugs, Olumiant (in Europe) for rheumatoid arthritis, Verzenio (abemaciclib) for metastatic breast cancer, and Emgality (galcanezumab), its CGRP antibody, for the preventive treatment of migraine are off to strong starts. In July 2019, Lilly gained FDA approval for Baqsimi, its glucagon nasal powder to treat severe hypoglycemia in diabetes patients. Baqsimi is the first and only nasally administered glucagon to be approved by the FDA. In October 2019, the FDA granted approval to Lilly's Reyvow (lasmiditan) oral tablets to treat acute migraine, thus boosting its portfolio of pain medicines. In 2020, Lilly expects to launch two medicines, Retevmo/selpercatinib (RET-altered lung and thyroid cancers) and Lyumjev/Ultra-rapid Lispro (type I and type II diabetes). While Retevmo was approved in the United States in May and is under review in EU, Lyumjev is approved both in the EU and United States.

Meanwhile, relatively newer drugs are also being evaluated or have been approved for additional indications/label expansions. These include Taltz (ixekizumab) (approved for axial spondyloarthritis in August 2019 and launched for psoriatic arthritis in 2017/2018), Cyramza (approved in United States for first-line EGFR mutation positive NSCLC in May 2020), and Verzenio (phase III for adjuvant breast cancer). Meanwhile, two phase III EMPEROR studies (outcomes studies) of Jardiance for chronic heart failure and a phase III study for chronic kidney disease are also ongoing. Olumiant is under review in Europe and Japan for atopic dermatitis and will be filed for the same in the United States later in 2020. It is also being studied in phase III studies for systemic lupus erythematosus.

▲ **Committed to Dividend and Cost Savings:** Even though quite a few of Lilly's drugs are facing generic competition, the company returned to annual dividend hikes in December 2016 and regularly returns excess cash through share repurchases. Cash distribution to shareholders, through dividends and share buybacks, was around \$2.6 billion in 2017, \$1.7 billion in 2018 and \$7 billion in 2019.

Lilly is actively pursuing in-licensing deals and acquisitions to drive near-to-medium term growth. The company is also resorting to cost cutting and headcount reduction to drive the bottom line. Lilly is regularly investing the savings in new drugs and overall growth of the company.

▲ **Emerging Markets and Japan to Drive Long-Term Growth:** Lilly is looking toward Japan and emerging markets to drive growth in the coming years. Cyramza and Verzenio are bringing in robust sales in Japan given high unmet need. The company also launched Trulicity, Taltz, Jardiance and Olumiant in Japan, which are driving sales growth in the country.

▲ **Favorable Debt Profile:** As of Mar 31, 2020, the company had \$17.23 billion in total debt (long term debt + current debt) and \$1.8 billion in cash + short term investments. This implies that its cash will fall slightly short to pay its short-term debt of \$3.2 billion in case of insolvency. However, its debt-to-total capital ratio was 81.4 as of Mar 31, 2020, which was lower than 84.1 at the end of 2019. A lower ratio indicates lower financial risk.

In 2020, Lilly's sales should be driven by higher demand for newer drugs including Trulicity, Taltz, Basaglar, Emgality and also newly launched Baqsimi and Reyvow.

Risks

- **Generic Threat to Key Products:** We are concerned about the patent expiration faced by several products in Lilly's portfolio. Products like Zyprexa, Cymbalta, Evista, and Gemzar are all facing declining sales due to generic competition. In 2017, Lilly lost patent protection for key drugs like Strattera, Axiron and Effient in the United States, which resulted in generic competition and consequent loss of sales. Lilly lost exclusivity for Cialis in September 2018 and generic versions entered the market in the same month resulting in rapid erosion of sales. Lilly lost exclusivity for Forteo in August 2019, making way for generic competition. Alimta sales outside the United States are being hurt due to loss of exclusivity in several countries. The drug's U.S. sales are also being affected by the entry of immuno-oncology agents in the market. The compound patent for Alimta expired in the United States in January 2017 and in major European countries and Japan in December 2015. Many generic manufacturers are looking for approval of generic versions of Alimta prior to the expiration of the vitamin regimen patent (expiring in June 2021 in Japan and European countries and in the United States in May 2022). Generic competition for Alimta following the loss of effective patent protection will cause a rapid decline in revenues from the product.
- **Pipeline Setbacks:** Lilly has had its share of development and regulatory setbacks. In October 2015, Lilly announced the termination of the development of its late-stage CETP inhibitor, evacetrapib. Lilly's decision was based on the recommendation of an independent data monitoring committee, which suggested that chances of meeting the primary endpoint were low.

In November 2016, Lilly's key candidate solanezumab failed to meet the primary endpoint in a late-stage study that was conducted in patients with mild dementia due to AD. Lilly decided to drop the development of solanezumab. In June 2018, Lilly discontinued two late-stage studies on Alzheimer's disease lanabecestat on recommendation of the independent data monitoring committee (IDMC).

In early 2018, Lartruvo, which had won conditional approval in 2016, failed to improve survival in patients with advanced soft tissue sarcoma in a late-stage confirmatory study, ANNOUNCE. With ANNOUNCE failing to confirm clinical benefit, Lilly stopped promoting Lartruvo, which sharply hurt sales of the drug in 2019.

- **Intense Competition:** In addition to generic threats, Lilly's products already face intense competition in the market from both large pharma companies as well as small and mid-sized companies. Competition for Lilly's diabetes care products has increased with the entry of Novo Nordisk's Victoza. Novo Nordisk's Ozempic/semaglutide, which was launched in 2018, is posing strong competition to Lilly's key growth driver, Trulicity. In fact, Lilly is seeing pricing pressure across all its diabetes products, which creates uncertainty around the franchise's long-term growth prospects. A number of competitors are entering the diabetes space. For example, with the approval of Merck/Pfizer's, Steglatro and its combinations, competition in the SGLT2 inhibitors class has increased.

Meanwhile, cancer drugs like Alimta and Cyramza are being impacted by competition from immuno-oncology agents in the United States. Meanwhile, Sanofi's biosimilar version of Humalog - Admelog – can create pricing pressure on Lilly's branded drug and erode its market share. Admelog was launched in 2018.

Last Earnings Report

Lilly Q1 Earnings Beat, Coronavirus May Mar Profits

Lilly reported first-quarter 2020 adjusted earnings per share of \$1.75, which comprehensively beat the Zacks Consensus Estimate of \$1.55. Earnings rose 32% year over year as higher R&D costs were offset by higher revenues.

Revenues in Detail

Revenues of \$5.86 billion beat the Zacks Consensus Estimate of \$5.51 billion. Sales grew 15% year over year (16% in constant currency), backed by strong volume trends, which offset the impact of lower realized prices.

Lower realized prices had a negative impact of 6% on sales. Volumes rose 22%, gaining from strong underlying demand trends for key growth products, augmented by higher patient and supply chain purchasing as people stocked medicines amid coronavirus-led lockdown. The coronavirus-related stockpiling mainly of Lilly's diabetes medicine, Trulicity and psoriasis medicine, Taltz increased Lilly's worldwide revenues by approximately \$250 million. Higher volumes of key growth products, namely Trulicity, Taltz, Jardiance, Basaglar, Emgality, and Verzenio compensated for lower sales of older products like Cialis and Forteo due to loss of exclusivity.

Foreign exchange had a modest negative impact on revenue growth this quarter.

Key growth products (products launched since 2014) drove 19% of revenue growth and represented nearly 51% total revenues, up from 46% in the previous quarter.

U.S. revenues rose 15% to \$3.33 billion while ex-U.S. revenues rose 15% to \$2.53 billion.

Among the established products, Forteo sales declined 13% to \$272.4 million. Humalog sales dropped 5% to \$695.8 million. Humulin sales rose 6% to \$315.7 million. Alimta sales rose 12% to \$560.1 million.

Among the growth products, Trulicity generated revenues of \$1.23 billion, up 40% year over year driven by higher volumes in the United States as well as ex-U.S. markets, which offset the impact of lower realized prices. COVID-19 related increased customer buying patterns and patient prescription trends benefited U.S. Trulicity sales by approximately \$30 million to \$40 million in the quarter.

Cyramza revenues were \$239.0 million, up 21% year over year driven by higher volumes in both U.S. and international markets.

Jardiance sales rose 31% to \$267.5 million, driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States.

Basaglar recorded revenues of \$303.7 million, up 21% year over year driven by higher volumes in both U.S. and international markets.

Taltz brought in sales of \$443.5 million, up 76% year over year as U.S. sales gained from higher demand and higher realized prices due to changes in estimates for rebates and discounts. Ex-U.S. sales were driven by increased volume, which offset the impact of lower realized prices. U.S. revenues for Taltz were favorably impacted by approximately \$20 million to \$25 million due to COVID-19.

Olumiant generated sales of \$139.7 million in the quarter compared with \$127.8 million in the previous quarter, backed by increased demand in international markets. Revenues outside the United States were \$128.4 million compared with \$114.9 million in the previous quarter. In the United States, Olumiant recorded sales of \$11.3 million compared with \$13.0 million in the previous quarter.

Verzenio generated sales of \$188.0 million in the quarter, up from \$179.1 million in the previous quarter driven by increased volume.

Emgality generated revenues of \$74.0 million in the quarter compared with \$66.3 million in the previous quarter. In the United States, Emgality sales were \$67.3 million compared with \$63.1 million in the previous quarter. Ex U.S. sales were \$6.7 million in the first quarter.

Lilly's newly launched product, Baqsimi, which is a glucagon nasal powder to treat severe hypoglycemia in diabetes patients, generated sales of \$17.8 million in the quarter.

Gross Margin & Operating Income

Adjusted gross margin was 80.3% in the quarter, up 10 basis points driven by favorable product mix and manufacturing efficiencies, which were partially offset by price and increased costs associated with COVID-19.

Operating income rose 32% year over year to \$1.76 billion. Operating margin was 30.1% in the quarter, up 390 bps year over year, gaining from impact of COVID-19 buying patterns.

Total operating expenses (including research and development and marketing, selling and administrative expenses) rose 7% in the quarter. Marketing, selling and administrative expenses rose 2% to \$1.55 billion due to cost control, partially offset by increased investment behind recent launches. R&D expense rose 13% to \$1.39 in the quarter due to higher development expenses for late-stage assets.

Adjusted effective tax rate was 13.6%, higher than 12.9% in the year-ago quarter.

2020 Guidance

However, despite the solid first-quarter results, the company maintained its full-year revenue guidance as it expects the coronavirus-related

Quarter Ending 03/2020

Report Date	Apr 23, 2020
Sales Surprise	6.32%
EPS Surprise	12.90%
Quarterly EPS	1.75
Annual EPS (TTM)	6.46

benefits seen in the first quarter to reverse over the course of 2020.

Importantly, Lilly warned that the economic consequences of the pandemic are uncertain and could hurt its profits in the future quarters of 2020 and potentially in 2021. In fact, reduced non-COVID healthcare activities due to business disruptions and global economic challenges emanating from the pandemic may hurt its profits, going forward. Lilly expects reduction in new prescription trends (as fewer patients visit a doctor) to be most significant in the second quarter in the United States and most European countries. The company expects headwinds from destocking as supply chains normalize from the recent demand surge and potential changes in segment mix in the United States due to rising unemployment in 2020.

Lilly upped the higher end of its 2020 adjusted earnings guidance from a range of \$6.70-\$6.80 per share to \$6.70 - \$6.90 to reflect the uncertainty of the impact of COVID-19 for the rest of the year. This indicates year-over-year growth in the range of 11% to 14%. However, the 2020 revenue guidance was maintained in the range of \$23.7 billion-\$24.2 billion. Gross margin guidance was maintained at approximately 81%. Adjusted tax rate is expected to be approximately 15%. Adjusted operating margin is expected to be 31% in 2020 (maintained).

The other expense guidance was lowered from a range of 100 million-250 million to \$0-150 million.

Marketing, selling and administrative expense guidance was maintained in the range of \$6.2 to \$6.4 billion. Research and development expense is still expected to be in the range of \$5.6 billion to \$5.9 billion.

Nonetheless, Lilly still expects revenue growth to be driven by higher demand for its growth drugs including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, Emgality, Baqsimi as well as potential revenues from new product launches. However, generic competition for several drugs, rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing, price reductions from increased utilization of patient affordability programs, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds expected in 2020. In the United States, prices are still expected to decline in a low-single digit range.

Coronavirus Related Research Efforts

Earlier in April, Lilly announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will evaluate Olumiant (baricitinib), as a potential treatment for hospitalized patients diagnosed with COVID-19. The drug will be evaluated in one of the arms of NIAID's Adaptive COVID-19 Treatment study. The study will first begin in April in the United States and then expand to additional sites in Europe and Asia. Data from the studies are expected in two months' time.

Alongside, Lilly has begun a phase II study on LY3127804, its monoclonal antibody that inhibits Angiotensin 2 (Ang2), in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome. The phase II study is already enrolling patients in the United States and data from the study is expected in the coming months.

In March, Lilly signed a deal with private biotech, AbCellera to co-develop antibody therapies to treat and prevent COVID-19. Lilly is working with AbCellera, NIH and academic partners to characterize virus-neutralizing antibodies isolated from the blood sample of a U.S. COVID-19 patient who recovered from the disease. The most advanced antibody in this program has now entered GMP manufacturing. Lilly plans to submit an IND to the FDA by the end of May to allow start of clinical testing in patients

Last month, Lilly halted enrollment in most ongoing studies and said that it will delay new study starts in order to allow doctors and healthcare facilities to focus on efforts to combat COVID-19. Along with the earnings release, Lilly clarified that enrollment in ongoing studies and new clinical study starts will resume in the second half of the year.

Recent News

FDA Approves Lyumjev – June 15

Lilly announced that the FDA has granted approval to Lyumjev, its ultra-rapid-acting lispro, a new fast-acting formulation of Lilly's insulin lispro (Humalog) to improve glycemic control in adults with type I and type II diabetes. The list price of Lyumjev will be the same as the list price of Humalog. Lyumjev was approved in the European Union in March this year.

Begins Phase III Study on Olumiant for Coronavirus – June 15

Lilly announced that the first patient has been dosed in a phase III study to evaluate its JAK inhibitor, Olumiant (baricitinib) as a potential treatment for hospitalized patients diagnosed with COVID-19. Olumiant is presently approved for the treatment of moderately to severely active rheumatoid arthritis (RA). The study, to be conducted in the United States, Europe and Latin America, will enroll 400 patients who have at least one marker of inflammation but do not require mechanical ventilation. In the study, patients will be given either 4 mg dose of Olumiant daily (with background therapy) or placebo (with background therapy) for up to 14 days or until discharge from the hospital. The study's primary endpoint will be to measure the proportion of patients who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation by Day 28. Data from the study is expected to be released in a few months.

The study will complement an already ongoing study of Olumiant with Gilead's (GILD) remdesivir being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) for hospitalized patients with COVID-19 infections. The NIAID study dosed the first patient last month.

Lebrikizumab Data at AAD Meeting – June 12

Lilly presented data from the phase IIb study of lebrikizumab in patients with moderate-to-severe atopic dermatitis at the virtual annual meeting of the American Academy of Dermatology. The data showed that the patients treated with lebrikizumab experienced clinically meaningful improvements in itch, sleep and quality of life.

Begins Outcomes Study on Tirzepatide – June 9

Lilly announced that the first patient dose has been delivered in a cardiovascular outcome study on its dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA) candidate, tirzepatide. The head-to-head phase III study (SURPASS-CVOT) will evaluate non-inferiority and superiority of tirzepatide to Lilly's blockbuster GLP-1 receptor agonist, Trulicity.

2nd Potential Coronavirus Antibody Candidate in Phase I – June 8

Lilly's partner China-based Junshi Biosciences has dosed the first healthy volunteer in phase I study on JS016, their antibody candidate for treating COVID-19.

Lilly signed the deal with Junshi last month to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19. Junshi has dosed the patient in a phase I study in China, while Lilly will soon begin its phase I study in United States.

The phase I studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with coronavirus.

While Junshi Biosciences has rights to products under the deal in Greater China, Lilly has exclusive development, manufacturing and distribution rights of products in the rest of the world. Lilly will study JS016 both as a monotherapy as well as in combination with other antibody treatments including LY-CoV555, its another potential COVID-19 antibody therapy candidate.

Begins Clinical Study on Coronavirus Antibody Candidate – June 1

Lilly announced that the first patients have been dosed in a phase I study on LY-CoV555, its lead antibody therapy candidate in collaboration with private biotech, AbCellera. Lilly signed the deal with AbCellera in March to create antibody therapies to treat and prevent COVID-19. LY-CoV555 is the first candidate to emerge from the collaboration. The phase I study on LY-CoV555 will evaluate its safety and tolerability in patients hospitalized with COVID-19.

Lilly said it developed the antibody in just three months after AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) identified virus-neutralizing antibodies isolated from the blood sample of a U.S. COVID-19 patient who recovered from the disease.

Results from the study are expected in June, following which it plans to initiate broader efficacy studies. Lilly is also beginning large-scale manufacturing of this potential therapy simultaneously with its R&D efforts. Lilly plans to study LY-CoV555 in more vulnerable populations if results of the phase I study are positive.

Cyramza Gets FDA Approval for First-Line Lung Cancer – May 29

Lilly announced that the FDA has approved its cancer drug, Cyramza (ramucirumab) for the first-line treatment of metastatic non-small cell lung cancer ("NSCLC") in patients with EGFR mutation. With the latest approval, Cyramza is now approved for six indications to treat certain types of lung, liver, stomach and colorectal cancers. In lung cancer, until now, Cyramza, in combination with docetaxel, was approved for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy.

Lilly filed a supplemental biologics license application (sBLA) seeking approval of Cyramza, a VEGF receptor 2 antagonist, in combination with Roche's Tarceva (erlotinib) in this indication based on data from the phase III RELAY study. In the RELAY study, the Cyramza combo reduced the risk of disease progression or death by 41% compared to Tarceva in this patient population.

FDA Approves Taltz for New Indication – May 28

Lilly announced that the FDA has approved its Taltz injection for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation. With the approval, Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA.

FDA Approves Tauvid (flortaucipir) – May 26

Lilly announced that the FDA has granted approval to Tauvid (flortaucipir), a diagnostic agent to image tau neurofibrillary tangles in the brain for use in patients being evaluated for Alzheimer's disease.

Valuation

Lilly's shares are 7.7% in the year-to-date period and 24.8% over the trailing 12-month period. Stocks in the Zacks sub-industry and sector are down 5.0% and 5.2%, respectively in the year-to-date period. Over the past year, stocks in the sub-industry are up 3.3% while those in the sector are down 2.7%.

The S&P 500 Index is down 5.5% in the year-to-date period but up 5.2% in the past year.

The stock is currently trading at 19.22X forward 12-month earnings per share which compares to 14.03X for the Zacks sub-industry, 22.01X for the Zacks sector and 21.92X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 26.36X and as low as 14.86X, with a 5-year median of 19.47X. Our Outperform recommendation indicates that the stock will perform better than the market. Our \$162 price target reflects 22.2X forward 12-month earnings per share.

The table below shows summary valuation data for LLY.

Valuation Multiples - LLY					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	19.22	14.03	22.01	21.92
	5-Year High	26.36	18.12	23.16	22.11
	5-Year Low	14.86	13.07	15.94	15.23
	5-Year Median	19.47	15.33	19.05	17.49
P/S F12M	Current	5.5	4.44	2.68	3.41
	5-Year High	6.43	4.83	3.74	3.44
	5-Year Low	3.33	3.92	2.21	2.53
	5-Year Median	4.22	4.39	2.91	3.02
P/B TTM	Current	42.34	5.97	4.1	4.16
	5-Year High	52.42	7.23	5.06	4.56
	5-Year Low	4.66	3.77	2.93	2.83
	5-Year Median	6.49	5.24	4.28	3.66

As of 6/15/2020

Industry Analysis Zacks Industry Rank: Top 6% (15 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
AbbVie Inc. (ABBV)	Outperform	2
AstraZeneca PLC (AZN)	Neutral	2
BristolMyers Squibb Company (BMY)	Neutral	2
GlaxoSmithKline plc (GSK)	Neutral	3
MerckCo., Inc. (MRK)	Neutral	3
Novo Nordisk AS (NVO)	Neutral	3
Novartis AG (NVS)	Neutral	3
Sanofi (SNY)	Neutral	3

Industry Comparison Industry: Large Cap Pharmaceuticals				Industry Peers		
	LLY	X Industry	S&P 500	AZN	BMY	NVO
Zacks Recommendation (Long Term)	Outperform	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	1	-	-	2	2	3
VGM Score	C	-	-	C	A	B
Market Cap	135.36 B	137.46 B	21.70 B	138.15 B	124.67 B	153.96 B
# of Analysts	6	2.5	14	5	5	4
Dividend Yield	2.09%	2.81%	1.95%	3.53%	3.27%	1.72%
Value Score	C	-	-	B	A	B
Cash/Price	0.01	0.05	0.06	0.03	0.14	0.01
EV/EBITDA	22.71	13.48	12.55	22.25	22.20	17.53
PEG Ratio	1.96	2.05	2.96	1.59	1.07	2.35
Price/Book (P/B)	42.34	3.90	2.99	11.31	2.49	19.16
Price/Cash Flow (P/CF)	19.98	11.06	11.61	16.62	12.55	23.15
P/E (F1)	20.78	14.96	21.21	25.96	8.97	24.31
Price/Sales (P/S)	5.86	4.02	2.26	5.47	4.02	8.17
Earnings Yield	4.81%	6.68%	4.43%	3.86%	11.14%	4.11%
Debt/Equity	4.37	0.67	0.76	1.32	0.86	0.05
Cash Flow (\$/share)	7.08	4.33	7.01	3.17	4.39	2.82
Growth Score	D	-	-	D	A	B
Hist. EPS Growth (3-5 yrs)	16.98%	8.53%	10.87%	-2.89%	21.90%	7.38%
Proj. EPS Growth (F1/F0)	12.72%	3.06%	-10.58%	15.89%	30.92%	9.35%
Curr. Cash Flow Growth	-7.51%	3.68%	5.46%	2.12%	36.74%	-0.50%
Hist. Cash Flow Growth (3-5 yrs)	9.27%	7.62%	8.55%	-0.86%	22.46%	7.63%
Current Ratio	1.11	1.11	1.29	0.75	1.66	1.00
Debt/Capital	81.39%	39.71%	45.06%	56.87%	46.16%	5.00%
Net Margin	23.97%	22.54%	10.54%	5.94%	3.08%	31.91%
Return on Equity	194.18%	32.02%	16.08%	33.97%	30.06%	73.87%
Sales/Assets	0.59	0.46	0.55	0.42	0.33	1.02
Proj. Sales Growth (F1/F0)	7.23%	4.76%	-2.59%	9.48%	59.03%	6.12%
Momentum Score	C	-	-	D	A	A
Daily Price Chg	-1.41%	0.67%	0.98%	2.27%	-1.90%	1.19%
1 Week Price Chg	-3.80%	-3.50%	-7.25%	-4.42%	-8.41%	0.19%
4 Week Price Chg	-10.41%	-1.52%	5.45%	-1.52%	-13.37%	2.51%
12 Week Price Chg	18.87%	27.85%	39.81%	35.74%	18.75%	29.70%
52 Week Price Chg	24.80%	14.29%	-4.47%	31.67%	14.29%	28.17%
20 Day Average Volume	4,025,953	2,925,162	2,587,370	5,992,156	14,519,442	1,389,512
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.50%	0.00%	0.00%
(F1) EPS Est 4 week change	0.00%	0.00%	0.00%	0.70%	0.03%	0.84%
(F1) EPS Est 12 week change	0.57%	-2.03%	-15.39%	0.50%	0.08%	-3.35%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	0.00%	-1.14%	-0.45%	0.00%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	D
Momentum Score	C
VGM Score	C

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.